Holzer Aton M, Kaplan Leonard L, Levis William R
Department of Medicine, Columbia University College of Physicians and Surgeons, New York, NY, USA.
J Drugs Dermatol. 2006 May;5(5):410-6.
For the past 40 years, dermatologists have safely used contact sensitizers such as dinitrochlorobenzene (DNCB), diphenylcyclopropenone (DPCP), and squaric acid dibutylester (SADBE) for the treatment of warts, alopecia areata, and even skin cancers. Most of these studies have utilized these powerful topical immunomodulators in acetone, a volatile solvent that precludes development of contact sensitizers as products. We have overcome these problems and stabilized these topical immunomodulators in a non-volatile, nonirritating GRAS (generally regarded as safe) vehicle. The current review article covers the traditional use of contact sensitizers for a variety of benign and malignant conditions and discusses possible mechanisms in relation to developments in modem molecular immunodermatology.
在过去40年里,皮肤科医生一直安全地使用接触性致敏剂,如二硝基氯苯(DNCB)、二苯基环丙烯酮(DPCP)和二丁基 squarate 酯(SADBE)来治疗疣、斑秃,甚至皮肤癌。这些研究大多在丙酮中使用这些强效局部免疫调节剂,丙酮是一种挥发性溶剂,这使得接触性致敏剂无法制成产品。我们已经克服了这些问题,并将这些局部免疫调节剂稳定在一种非挥发性、无刺激性的公认安全(GRAS)载体中。这篇综述文章涵盖了接触性致敏剂在各种良性和恶性疾病中的传统用途,并讨论了与现代分子免疫皮肤病学发展相关的可能机制。